6 recruiting, 5 completed, 4 terminated, 3 active not recruiting. 19 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Recruiting 6, Completed 5, Terminated 4, Active not recruiting 3, Withdrawn 1 |
| Phase 2 | 12 | Recruiting 4, Active not recruiting 3, Completed 3, Terminated 2 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC HLX3901 - SCLC, NEC | Phase 1 | Recruiting | Shanghai Henlius Biotech | 138 | 2026-04-17 | 2026-07-08 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer ZL-1310, Atezolizumab, Carboplatin - SCLC | Phase 1 | Recruiting | Zai Lab (Shanghai) Co., Ltd. | 339 | 2024-01-23 | 2026-10-16 |
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Palbociclib Oral Product, TAS-116 - Advanced Breast Cancer, Treatment-Refractory Solid Tumors | Phase 1 | Withdrawn | Brown University | 2023-09-12 | 2024-09-19 | |
| GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi) - SCLC, Malignant Melanoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 23 | 2022-11-17 | 2026-06-18 |
| Study of Oral MRT-2359 in Selected Cancer Patients Oral MRT-2359 - NSCLC, SCLC | Phase 1 / Phase 2 | Active not recruiting | Monte Rosa Therapeutics, Inc | 174 | 2022-10-12 | 2026-11-06 |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Carboplatin, Cisplatin, Etoposide - SCLC | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 60 | 2021-09-07 | 2023-07-19 |
| Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer Nivatrotamab - SCLC | Phase 1 / Phase 2 | Terminated | Y-mAbs Therapeutics | 3 | 2021-08-17 | 2023-08-14 |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors JAB-8263 - NSCLC, SCLC | Phase 1 / Phase 2 | Recruiting | Jacobio Pharmaceuticals Co., Ltd. | 152 | 2021-05-07 | 2026-01-09 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Nivolumab, Plinabulin, Ipilimumab - Lung Cancer, SCLC | Phase 1 / Phase 2 | Completed | Salma Sabbour | 39 | 2018-09-06 | 2026-01-20 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Lurbinectedin, Irinotecan - Advanced Solid Tumors, Glioblastoma | Phase 1 / Phase 2 | Completed | PharmaMar | 316 | 2016-05-06 | 2025-07-09 |
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Olaparib, MEDI4736, Bevacizumab - Ovarian, Breast | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 264 | 2016-03-17 | 2026-07-14 |
| A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection MRX34 - Primary Liver Cancer, SCLC | Phase 1 | Terminated | Mirna Therapeutics, Inc. | 155 | 2013-04-01 | 2016-09-27 |
| A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy pemetrexed, cisplatin, radiation - Small Cell Lung Cancer, Carcinoma, Small Cell | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 9 | 2007-02-01 | 2009-10-28 |
| BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors BB-10901 - Ovarian Cancer, Merkel Cell Carcinoma | Phase 1 | Completed | ImmunoGen, Inc. | 97 | 2002-03-01 | 2015-03-26 |
Small Cell Lung Carcinoma (7) · Ovarian Neoplasms (4) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Hepatocellular (1)
Neoplasms by Site (14) · Neoplasms (12) · Lung Diseases (8) · Neoplasms by Histologic Type (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (6)
Carboplatin (2) · Cisplatin (2) · PM 01183 (2) · berzosertib (2) · Bevacizumab (1) · Etoposide (1) · Ipilimumab (1) · Irinotecan (1) · NPI 2358 (1) · Nivolumab (1) · Pemetrexed (1) · Radiation (1) · TAS-116 (1) · atezolizumab (1) · durvalumab (1)
National Cancer Institute (NCI) (2) · Y-mAbs Therapeutics (2) · AstraZeneca (1) · Brown University (1) · Eli Lilly and Company (1) · Gilead Sciences (1) · ImmunoGen, Inc. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Mirna Therapeutics, Inc. (1) · Monte Rosa Therapeutics, Inc (1) · PMV Pharmaceuticals, Inc (1) · Peking University First Hospital (1) · PharmaMar (1) · Salma Sabbour (1)
United States (14) · China (5) · France (4) · Spain (4) · South Korea (3) · United Kingdom (3) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · Switzerland (2) · Australia (1) · Belgium (1) · Canada (1) · Romania (1)
Anish Thomas, M.D. (2) · Marc Fellous, MD (1) · O'Neill VIncent, MD (1) · Paul C. Lorigan, MD (1) · Salma Jabbour, MD (1) · Susan Domchek, MD (1) · Taofeek K Owonikoko, MD/PhD (1) · Wafik El-Deiry, MD, PhD, FACP (1) · Yariv Houvras, MD, PhD (1)
PMID 32238921, PMID 32771088, PMID 34187739, PMID 35756843, PMID 37491889, PMID 37939124, PMID 39173229, PMID 40543428, PMID 40932470, PMID 40963055, PMID 41740031, PMID 41791703, PMID 42081171
2015 (1)